Global POEMS Syndrome Market - 2022-2029

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	160 Pages	DataM Intelligence 4Market Research LLP	June, 2022	DTAM17210669

Best Price Guarantee
Price	from $4,350
Length	160 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	June, 2022
SKU	DTAM17210669

Global POEMS Syndrome Market - 2022-2029

Market Overview

The global POEMS syndrome market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes) syndrome is a blood disorder that affects several body systems. Abnormal plasma cells produce excessive quantities of antibody proteins to collect in the blood in this uncommon illness. A high concentration of these proteins in the blood can harm nerves and cause organ systems to malfunction. POEMS syndrome does not have conventional treatment. Radiation therapy, chemotherapy, and hematopoietic cell transplantation are alternatives for people with POEMS syndrome.

Market Dynamics

Innovation in the treatment of POEMS Syndrome is expected to drive market growth.

POEMS treatment, like multiple myeloma treatment, aims to eradicate the offending plasma cell clone. High-dose melphalan followed by autologous hematopoietic cell transplant (HCT) provides the best long-term results for eligible individuals. Moreover, patients who cannot tolerate HCT are given plasma cell-directed treatment. Immunomodulatory medicines in various combinations include lenalidomide, proteasome inhibitors like bortezomib, dexamethasone, and cyclophosphamide. Therefore, it has increased the demand for the drug. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Lack of awareness of the disease among the population, side effects of the drugs and restricted access to necessary healthcare facilities are some factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The pandemic's management had an indirect impact on major diseases. In reality, fear of the epidemic's catastrophe is causing many sufferers to put off seeking treatment. Aside from chronic patient monitoring, the practitioner's primary goal is to detect emergency circumstances. The POEMS syndrome with plasmacytoma lytic bone lesion is still a rare occurrence. Radiotherapy is advised as a treatment strategy with variable success in patients with less than three isolated bone plasmacytomas.

In contrast, there is a delay in treating POEMS Syndrome as there is contact between the patient and the doctor. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Chemotherapy segment is expected to hold the largest market share in POEMS syndrome market

The chemotherapy segment is expected to dominate in 2021. The segment is benefited because high-dose chemotherapy with ASCT can achieve excellent clinical responses, with a significant improvement of neuropathy, complete hematologic response (CRH) in 60% of POEMS syndrome patients, and complete VEGF response (CRV) in 50%. For instance, Melphalan is an alkylation agent commonly used to treat plasma diseases such as myeloma and amyloidosis. MDex (Melphalan plus dexamethasone) produced a 100% neurological response. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global POEMS syndrome market

In 2021, North America accounted for the highest revenue share. The advancement in the diagnosis of the disease, well-established clinical facilities, and clinical trials conducted for the treatment and product launches by the market players in the region are some of the factors the market is expected to boost in the forecast period. For instance, Patients with POEMS usually have a long-term, progressively deteriorating, length-dependent, and demyelinating peripheral neuropathy. While the syndrome is comparable to the more frequent CIDP, it differs in several ways. POEMS patients had more axonal degeneration, neuropathic pain, and lower-limb atrophy than CIDP patients, although cranial nerve involvement and dysautonomia are significantly less common. A crucial screening technique for diagnosing POEMS syndrome is serum or urine immunofixation electrophoresis. The symptoms listed above, along with a lambda light chain-restricted immunofixation electrophoresis profile, strongly imply a diagnosis.

Additionally, Geneyork Pharmaceutical, a privately held specialty pharmaceutical company that develops, contract manufactures, and sells finished pharmaceutical products, launched the commercial shipment of Generic Deltasone (Prednisone) Tablets in the United States on February 2, 2020, in collaboration with Lannett Company, Geneyork's U.S. distribution and marketing partner. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the POEMS syndrome market are Pfizer, Inc., Bristol-Myers Squibb Company, Baxter, Genentech USA, Inc., Takeda Pharmaceuticals U.S.A., Inc., Oncopeptides AB. Acrotech Biopharma, LLC., LGM PHARMA , Jubilant Cadista Pharmaceuticals Inc.

Bristol-Myers Squibb Company:

Overview:

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company. It is headquartered in New York City. The company has advancements in oncology, hematology, immunology and cardiovascular disease. It is dedicated to helping patients prevail over serious diseases through its diverse and promising pipelines and new scientific platforms. Bristol Myers Squibb is at the forefront of oncology with an extensive portfolio of investigational compounds and approved medicines. Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs is a subsidiary of Bristol Myers Squibb.

Product Portfolio:

REVLIMID (lenalidomide): Lenalidomide is an effective therapy against malignant plasma cells and a potent agent against proinflammatory and proangiogenic cytokines.

Why Purchase the Report?

Visualize the composition of the POEMS syndrome market segmentation by diagnosis type, treatment type, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in POEMS syndrome market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of POEMS syndrome market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global POEMS syndrome market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Diagnosis Type
3.2. Market Snippet by Treatment Type
3.3. Market Snippet by End user
3.4. Market Snippet by Distribution channel
3.5. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Innovation in the treatment of POEMS Syndrome is expected to drive market growth.
4.1.2. Restraints:
4.1.2.1. Lack of awareness of the disease among the population is expected to hamper in the forecast period.
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Supply Chain Analysis
5.2. Pricing Analysis
5.3. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Diagnosis Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
7.1.2. Market Attractiveness Index, By Diagnosis Type Segment
7.2. Electromyelogram (EMG)*
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Blood and/or urine tests
7.4. Imaging
7.4.1. X-ray
7.4.2. CT scan
7.4.3. Others
7.5. Physical exam
7.6. Biopsy
7.7. Others
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Chemotherapy*
8.2.1. Cyclophosphamide
8.2.2. Pepaxto (melphalan flufenamide
8.2.3. Others
8.2.4. Introduction
8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Radiation therapy
8.4. Physical therapy
8.5. Others
9. By End user
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
9.1.2. Market Attractiveness Index, By End user Segment
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Centers
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel Segment
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Product Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. Pfizer Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. Bristol-Myers Squibb Company
13.3. Baxter
13.4. Genentech USA, Inc.
13.5. Takeda Pharmaceuticals U.S.A., Inc.
13.6. Oncopeptides AB
13.7. Acrotech Biopharma, LLC.
13.8. LGM PHARMA
13.9. Jubilant Cadista Pharmaceuticals Inc.
LIST NOT EXHAUSTIVE
14. Global POEMS Syndrome Market – DataM
14.1. Appendix
14.2. About Us and Applications
14.3. Contact Us